Meeting the biologic challenge of colorectal metastases

Clinical and Experimental Metastasis

Volumn 29, Issue 7, 2012, Pages 821-839

  Wanebo, Harold J ^a   LeGolvan, Mark ^b,c   Paty, Philip B ^d   Saha, Sukamal ^e   Zuber, Markus ^f   D'Angelica, Michael I ^d   Kemeny, Nancey E ^d  

^a Landmark Medical Center   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF MICHIGAN FLINT   (United States)

^f KANTONSSPITAL   (Switzerland)

Author keywords

Colorectal cancer; Regional therapy; Sentinel lymph nodes liver metastasis; Signaling pathways

Indexed keywords

APC PROTEIN; B RAF KINASE; BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; CELL ADHESION MOLECULE; CETUXIMAB; CYTIDINE PHOSPHATE; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MATRIX METALLOPROTEINASE; MS1 PROTEIN; OXALIPLATIN; PANITUMUMAB; PLACEBO; PROTEIN P53; SMAD4 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ANEUPLOIDY; ANGIOGENESIS; APOPTOSIS; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CARCINOGENESIS; CATHETER COMPLICATION; CATHETER THROMBOSIS; CHOLECYSTITIS; CLINICAL EVALUATION; COLON CANCER; COLORECTAL CANCER; COLORECTAL METASTASIS; CONFERENCE PAPER; DIAGNOSTIC TEST; EPITHELIAL MESENCHYMAL TRANSITION; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HEPATIC ARTERY; HEPATIC ARTERY THROMBOSIS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE RESECTION; LIVER METASTASIS; LYMPH NODE METASTASIS; METASTASIS; MISMATCH REPAIR; NUCLEIC ACID AMPLIFICATION; ONE STEP NUCLEIC ACID DIAGNOSTIC SYSTEM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; RECTUM CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; SURGICAL APPROACH; SURVIVAL TIME; TREATMENT RESPONSE;

ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SENTINEL LYMPH NODE BIOPSY; SIGNAL TRANSDUCTION; SMAD PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84868198400     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9517-x     Document Type: Conference Paper

References (134)

1. Riles, LAG, Melbert D, Krapcho M et al (2010) SEER Cancer Statistics Review, 1975-2005. National Cancer Institute, Bethesda MD, based on November 2007 SEER data submission. Ann Surg Oncol 17:492
2. Nordlinger B, Rougier P (2002) Liver metastases from colorectal cancer: The turning point. J Clin Oncol 20:1442-1445
3. Chua TC et al (2010) Systematic review of randomized and non randomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 17:492-501
4. Andre T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343-2351
5. Douillard JY et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. A multicoated randomized trial. Lancet 355:1041-1047
6. Goldberg RM et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30
7. Bokemeyer C et al (2009) Fluorouracil, leucovorin and oxaliplatin with and without Cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671
8. Hurwitz H et al (2004) Bevacizumab in combination with Oxaliplatin-cancer. A randomized phase III study. J Clin Oncol 350:2335-2342
9. Saltz LB et al (2008) Bevacizumab in combination with Oxaliplatin based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019
10. Wanebo H, Berz D (2010) Neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors. J Surg Oncol 102:891-897
11. Adam R et al (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8:347-353
12. Adam R et al (2004) Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052-1061; discussion 1061-1064
13. Nordlinger B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomized controlled trial. Lancet 371:1007-1016
14. Adam R et al (2008) Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? J Clin Oncol 26:1635-1641
15. Gruenberger B et al (2008) Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 8:120
16. Blazer DG III et al (2008) Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26:5344-5351
17. Folkman J (2007) Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286
18. Olsson AK et al (2006) VEGF receptor signaling-in control of vascular function. Nat Rev Mol Cell Biol 7:359-371
19. Hurwitz HI et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: An active regiment for first line metastatic colorectal cancer. J Clin Oncol 23:3502-3508
20. Van Cutsem E et al (2009) Safety and efficacy of first-line Bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer. The BEAT study. Ann Oncol 20:1842-1847
21. Tol J, Punt CJ (2010) Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review. Clin Ther 32:437-453
22. Cunningham D et al (2004) Cetuximab monotherapy and Cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
23. Van Cutsem E, Lang I, D'haens G et al (2008) KRAS stats on efficacy in the first-line treatment of patient with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without Cetuximab: The CRYSTAL experience. J Clin Oncol 26:abstr. 2
24. Van Cutsem E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417
25. Bardelli A, Siena S (2010) Molecular mechanisms of resistance in Cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254-1261
26. Sartore-Bianchi A et al (2009) P1K3CA mutations in colorectal cancer are associated with clinical resistance to EGFR targeted monoclonal antibodies. Cancer Res 69:1851-1857
27. Laurent-Puig P et al (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from Cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924-5930
28. Khambata-Ford S et al (2007) Expression of epiregulin and amphineegulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with Cetuximab. J Clin Oncol 25:3230-3237
29. LeGolvan MP, Resnick M (2010) Pathobiology of colorectal hepatic metastases with an emphasis on prognostic factors. JSO 102:898-908
30. Geiger TR, Peeper DS (2009) Metastasis mechanisms. Biochim Biophys Acta 1796:293-308
31. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871-890
32. Jechlinger M, Grunert S, Tamir IH et al (2003) Expression profiling of epithelial plasticity in tumor progression. Oncogene 22:7155-7169
33. Spaderna S, Schmalhofer O, Hlubek F et al (2006) A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 131: 830-840
34. Lohi J (2001) Laminin-5 in the progression of carcinomas. J Int Cancer 94:763-767
35. Sordat I, Rousselle P, Chaubert P et al (2000) Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int J Cancer 88:708-717
36. Guess CM, Quaranta V (2009) Defining the role of laminin-332 in carcinoma. Matrix Biol 28:445-455
37. Miyazaki K (2006) Laminin-5 (laminin-332): Unique biological activity and role in tumor growth and invasion. Cancer Sci 97:91-98
38. Paschos KA, Canovas D, Bird NC (2010) The engagement of selectins and their ligands in colorectal cancer liver metastases. J Cell Mol Med 14:165-174
39. Paschos KA, Canovas D, Bird NC (2009) The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 21:665-674
40. Dorudi S, Hanby AM, Poulsom R et al (1995) Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 71:614-616
41. Delektorskaya VV, Perevoshchikov AG, Golovkov DA, Kushlinskii NE (2005) Expression of E-cadherin, beta-catenin, and CD-44v6 cell adhesion molecules in primary tumors and metastases of colorectal adenocarcinoma. Bull Exp Biol Med 139:706-710
42. Han SA, Chun H, Park CM et al (2006) Prognostic significance of beta-catenin in colorectal cancer with liver metastasis. Clin Oncol 18:761-767
43. Suzuki H, Masuda N, Shimura T et al (2008) Nuclear betacatenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma. Anticancer Res 28:1821-1830
44. Choi HN, Kim KR, Lee JH et al (2009) Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta- catenin complex. Oncol Rep 21:57-63
45. Barczyk M, Carracedo S, Gullberg D (2010) Integrins. Cell Tissue Res 339:269-280
46. Robertson JH, Iga AM, Sales KM et al (2008) Integrins: A method of early intervention in the treatment of colorectal liver metastases. Curr Pharm Des 14:296-305
47. Koretz K, Schlag P, Boumsell L, Möller P (1991) Expression of VLA-alpha 2, VLA-alpha 6, and VLA-beta 1 chains in normal mucosa and adenomas of the colon, and in colon carcinomas and their liver metastases. Am J Pathol 138:741-750
48. Gong J, Wang D, Sun L et al (1997) Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ 8:83-90
49. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 92:827-839
50. Zucker S, Vacirca J (2004) Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23:101-117
51. Pesta M, Holubec L, Topolcan O et al (2005) Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res 25:3387-3391
52. Stein U, Schlag PM (2007) Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 176:61-80
53. Rudmik LR, Magliocco AM (2005) Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol 92: 347-359
54. Delektorskaya VV, Perevoshchikov AG, Golovkov DA, Kushlinskii NE (2007) Prognostic significance of expression of matrix metalloproteinase in colorectal adenocarcinomas and their metastases. Bull Exp Biol Med 143:455-458
55. Golovkov DA (2009) Key enzymes of the extracellular matrix in colorectal cancer. Bull Exp Biol Med 147:353-356
56. Gentner B, Wein A, Croner RS et al (2009) Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res 29:67-74
57. Illemann M, Bird N, Majeed A et al (2009) Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer 124:1860-1870
58. Friedmann Y, Vlodavsky I, Aingorn H et al (2000) Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 157:1167-1175
59. Di Renzo MF, Olivero M, Giacomini A et al (1995) Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clinical Cancer Res 1:147-154
60. Herynk MH, Tsan R, Radinsky R, Gallick GE (2003) Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis 20:291-300
61. Stein U, Walther W, Arlt F et al (2009) MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15:59-67
62. Siena S, Sartore-Bianchi A, Di Nicolantonio F et al (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308-1324
63. Yamada M, Ichikawa Y, Yamagishi S et al (2008) Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clinical Cancer Res 14:2351-2356
64. Sullivan LA, Brekken RA (2010) The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2:165-175
65. Berney CR, Yang JL, Fisher RJ et al (1998) Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. Anticancer Res 18:973-977
66. Maeda K, Nishiguchi Y, Yashiro M et al (2000) Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 5:373-378
67. Thomas M, Augustin H (2009) The role of the angiopoietins in vascular morphogenesis. Angiogenesis 12:125-137
68. Ahmad SA, Liu W, Jung YD et al (2001) Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 92:1138-1143
69. Chung YC, Hou YC, Chang CN, Hseu TH (2006) Expression and prognostic significance of angiopoietin in colorectal carcinoma. J Surg Oncol 94:631-638
70. Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: Molecular basis of colorectal cancer. New Engl J Med 361:2449-2460
71. Kastrinakis W, Ramchurren N, Rieger K et al (1995) Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 11:647-652
72. Heide I, Thiede C, Sonntag T et al (1997) The status of p53 in the metastatic progression of colorectal cancer. Eur J Cancer 33: 1314-1322
73. Peller S, Halevy A, Slutzki S et al (1995) p53 mutations in matched primary and metastatic human tumors. Mol Carcinog 13:166-172
74. de Jong KP, Gouw AS, Peeters PM et al (2005) P53 mutation analysis of colorectal liver metastases: Relation to actual survival, angiogenic status, and p53 overexpression. Clin Cancer Res 11:4067-4073
75. Sah NK, Khan Z, Khan GJ, Bisen PS (2006) Structural, functional and therapeutic biology of survivin. Cancer Lett 244:164-171
76. Fang Y, Lu Z, Wang G et al (2009) Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 24:875-884
77. Viehl CT, Guller U, Cecini R, Langer I, Ochsner A, Terracciano L, Riehle HM, Laffer U, Oertli D, Zuber M (2011) Sentinel lymph node procedure leads to upstaging of patients with resectable colon cancer. Results of the Swiss prospective, multicenter study sentinel lymph node procedure in colon cancer. Ann Surg Oncol 2011; published online 10 February 2012. doi: 10.1245/s10434-012-2233-6
78. Notomi T, Okayama H, Masubuchi H et al (2000) Loop-mediated isothermal amplification of DNA. Nucleic Acids Res 105: 215-222
79. Tsujimoto M, Nakabayashi K, Yoshidome K et al (2007) Onestep nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 13:4807-4816
80. Osako T, Iwase T, Kimura K et al (2011) Intraoperative molecular assay for sentinel lymph node metastases in early stage breast cancer: A comparative analysis between one-step nucleic acid amplification whole node assay and routine frozen section histology. Cancer 117:4365-4374
81. Tamaki Y, Akiyama F, Iwase T et al (2009) Molecular detection of lymph node metastases in breast cancer patients: Results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res 15:2879-2884
82. Croner RS, Schellerer V, Demund H et al (2010) One step nucleic acid amplification (OSNA)-a new method for lymph node staging in colorectal carcinomas. J Transl Med 8:83
83. Yamamoto H, Sekimoto M, Oya M et al (2011) OSNA-based novel molecular testing for lymph node metastases in colorectal cancer patients: Results from a multicenter clinical performance study in Japan. Ann Surg Oncol 18:1891-1898
84. Guller U, Zettl A, Worni M, Langer I, Cabalzar-Wondberg D, Viehl CT, Demartines N, Zuber M (2012) Molecular investigation of lymph nodes in colon cancer patients using one-step nucleic acid amplification (OSNA): A new road to better staging? Cancer; accepted for publication
85. Rocha FG, D'Angelica M (2010) Treatment of liver colorectal metastases: Role of laparoscopy, radiofrequency ablation, and microwave coagulation. J Surg Oncol 102(8):968-974
86. Scheele J, Stangl R, Altendorf-Hofmann A (1990) Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg 77(11):1241-1246
87. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M (2006) Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies. Br J Cancer 94(7):982-999
88. Silen W (1989) Hepatic resection for metastases from colorectal carcinoma is of dubious value. Arch Surg 124(9):1021-1022
89. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575-4580
90. Catenacci DV, Kozloff M, Kindler HL, Polite B (2011) Personalized colon cancer care in 2010. Semin Oncol 38(2): 284-308
91. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230(3):309-318
92. House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, D'Angelica MI (2010) Survival after hepatic resection for metastatic colorectal cancer: Trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 210(5):744-752, 752-755
93. Gold JS, Are C, Kornprat P, Jarnagin WR, Gönen M, Fong Y, DeMatteo RP, Blumgart LH, D'Angelica M (2008) Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: Trends in treatment over time in 440 patients. Ann Surg 247(1):109-117
94. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, OvermanMJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN (2011) High survival rate after two-stage resection of advanced colorectal liver metastases: Response-based selection and complete resection define outcome. J Clin Oncol 29(8):1083-1090
95. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, Hägerstrand I, Ranstam J, Bengmark S (1986) Determinants of survival in liver resection for colorectal secondaries. Br J Surg 73(9):727-731
96. Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, Malka D, Pignon JP, Lasser P (2005) Hepatic and extrahepatic colorectal metastases: When resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 12(11):900-909
97. Carpizo DR, Are C, Jarnagin W, Dematteo R, Fong Y, Gönen M, Blumgart L, D'Angelica M (2009) Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: Results in 127 patients treated at a single center. Ann Surg Oncol 16(8):2138-2146
98. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H (2004) Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 240(6):1052-1061
99. Pawlik TM, Abdalla EK, Ellis LM, Vauthey JN, Curley SA (2006) Debunking dogma: Surgery for four or more colorectal liver metastases is justified. J Gastrointest Surg 10(2):240-248
100. Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D'Angelica M (2007) Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 14(3):1151-1160
101. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241(5):715-722
102. Are C, Gonen M, Zazzali K, Dematteo RP, Jarnagin WR, Fong Y, Blumgart LH, D'Angelica M (2007) The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg 246(2):295-300
103. American Cancer Society (2011) Cancer facts & figures 2011. American Cancer Society, Atlanta
104. Kemeny, N.E., Kemeny, M. M., Lawrence, T.S., Liver Metastases, in Clinical Oncology, M.D. Abeloff, Armitage, J., Niederhuber, J., Kastan, M., McKenna, W.G., Editor. 2004, Elsevier: Philadelphia
105. Weiss L, Grandmann E, Torhost J et al (1986) Hematogenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol 150:195-203
106. Weiss L (1989) Metastatic inefficiency and regional therapy for liver metastases from colorectal carcinoma. Regul Cancer Treat 2:77-81
107. Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30(5):969-977
108. Ackerman NB (1974) The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 75(4):589-596
109. Sigurdson ER et al (1987) Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 5(11):1836-1840
110. Ensminger WD (2002) Intrahepatic arterial infusion of chemotherapy: Pharmacologic principles. Semin Oncol 29(2):119-125
111. Ensminger WD, Gyves JW (1983) Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10(2):176-182
112. McCollins JM (1984) Pharmacologic rationale for regional drug delivery. J Clin Oncol 2(5):498-504
113. Collins JM (1986) Pharmacologic rationale for hepatic arterial therapy. Recent Results Cancer Res 100:140-147
114. Rodic R, Gomez-Abuin G, Rougier P et al (2004) Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: Comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs 15:647-650
115. Ducreux M, Ychou M, Laplanche A et al (2005) Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: A trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 23:4881-4887
116. Van Riel JMGH, Van Groeningen C, Kedde M et al (2004) Continuous administration of irinotecan by hepatic arterial infusion: A phase I and pharmacokinetic study. Clin Cancer Res 8:405-412
117. Tandon R, Bunnell I, Copper R (1973) The treatment of metastatic carcinoma of the liver by percutaneous selective hepatic artery infusion of 5-fluorouracil. Surgery 73:118
118. Ensminer W, Niederhuber J, Dakhil S, Thrall J, Wheeler R (1981) Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 65:393-400
119. Power DG, Kemeny NE (2009) The role of floxuridine in metastatic liver disease. Mol Cancer Ther 8(5):1015-1025
120. Kemeny N et al (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24(9):1395-1403
121. Mocellin S, Pilati P, Lise M et al (2007) Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: The end of an era? J Clin Oncol 25:5649-5654
122. Allen PJ, Nissan A, Picon AI et al (2005) Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: An institutional experience of 544 consecutive cases. J Am Coll Surg 201:57-65
123. Northover J, Terblance J (1979) A new look at the arterial supply of the bile duct in man and its surgical implications. Br J Surg 66:379-384
124. Kemeny N (1992) Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes! In: DeVita VT, Hellman S, Rosenberg SA (eds) Important advances in oncology, chap 12. J.B. Lippincott Co., New York, pp 207-228
125. Mitry E, Fields AL, Bleiberg H et al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A pooled analysis of two randomized trials. J Clin Oncol 26:4906-4911
126. Power DG, Kemeny NE (2010) The role of adjuvant therapy after resection of colorectal cancer liver-metastases. J Clin Oncol 28(13):2300-2309
127. Kemeny N, Huang Y, Cohen AM et al (1999) Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341(27):2039
128. Kemeny NE, Gonen M (2005) Hepatic arterial infusion after liver resection [7]. N Engl J Med 352(7):734-735
129. Kemeny MM, Adak S, Gray B et al (2002) Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. J Clin Oncol 20(6):1499-1505
130. Lygidakis NJ, Sgourakis G, Vlachos L et al (2001) Metastatic liver disease of colorectal origin: The value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 48(42):1685-1691
131. Lorenz M, Muller HH, Schramm H et al (1998) Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 228(6): 756-762
132. Kemeny NE, Jarnagin W, Gonen M et al (2005) Phase I trial of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) in combination with systemic oxaliplatin (OXAL), fluorouracil (FU) ? leucovorin (LV) after resection of hepatic metastases from colorectal cancer. J Clin Oncol 23(16S):Abstract No: 3579
133. Kemeny NE, Jarnagin WR, Capanu M, Fong Y, Gewirtz AN, Dematteo RP (2011) D'Angelica MI Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol 29:884-889
134. House MG, Kemeny NE, Gonen M, Fong Y, Allen PJ, Paty PB, DeMatteo RP, Blumgart LH, Jarnagin WR, D'Angelica MI (2011) Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg 254(6): 851-856